BMS, SyntheX partner on molecular degraders

Oct. 4, 2022

Emerging biotech SyntheX and Bristol Myers Squibb will be working together to develop and commercialize targeted protein degradation (TPD) therapeutics.

Specifically, the partnership will leverage San Francisco-based SyntheX’s ToRNeDO platform to hopefully discover molecular glue degraders against targets of interest. The proprietary technology uses synthetic biology to build next-generation discovery engines by using intracellular drug selection as opposed to in vitro screening.

Using a pre-specified E3 ligase and a substrate of interest, the company can discover functional molecular glues for a variety of human E3 ligases, which play a pivotal role in the regulation of many different crucial cellular pathways such as p53, implicated in cancer. 

As a part of the agreement, SyntheX will receive an upfront sum of cash and investment, and is eligible for performance-based milestone payments totaling $550 million.